Biochemical Markers of Osteoporosis

(based on 918 customer ratings)

Author: Lynne Brodeur, MA, MLS(ASCP)CM
Reviewers: Laura Merritt, MS, MT(ASCP); Elizabeth Hart, MA, MLS(ASCP)CM

Osteoporosis is the most common metabolic bone disease in the United States. It is a skeletal disease in which the bones become brittle and prone to fracture. This course discusses the clinical background and epidemiology of osteoporosis. Various risk factors as well as signs and symptoms are presented. The traditional screening recommendations along with the current biochemical markers for osteoporosis are discussed in this course.

Continuing Education Credits

Objectives

  • Discuss the clinical background of osteoporosis.
  • Discuss the epidemiology of osteoporosis, based on age, sex, race, and other factors.
  • Identify the three types of osteoporosis.
  • Identify the various risk factors for osteoporosis.
  • Describe the signs and symptoms of osteoporosis.
  • List the various screening recommendations established for osteoporosis.
  • Discuss the clinical results.

Course Outline

  • The clinical background of osteoporosis.
      • Clinical Background
    • Bones
      • Function of bones and the role of osteoclasts and osteoblasts
      • Function of bones and the role of osteoclasts and osteoblasts (cont'd)
      • What is the most common metabolic bone disease in the United States?
      • Osteoporosis is a skeletal disease in which bone density is increased to the point where fractures occur without severe stress or injury to the bones.
  • Epidemiology of osteoporosis
      • Epidemiology
      • Epidemiology (cont'd)
      • Epidemiology (cont'd)
      • Male Statistics
      • In the United States, osteoporosis is an issue for 24 million Americans. What are the most common types of fractures that result from this disease?
      • Jane is an 80-year-old female with osteoporosis and John is an 80-year-old male. Why does Jane have osteoporosis and John does not?
  • The Three Types of Osteoporosis
      • Type 1
      • Type 2
      • Type 3
      • Mary is a 56-year-old menopausal woman who also has a disorder of her parathyroid glands. Given her condition which two substances have the potential ...
      • Vivian is a 62-year-old postmenopausal woman with osteoporosis. Other than this, she is in excellent health and takes no medications. Given her age an...
  • Risk factors associated with osteoporosis
      • Gender/ Age and Race
      • Family History and Bone Structure
      • Medications (glucocorticoids)
      • Medications (breast & prostate cancer drugs)
      • Medications (acid reflux)
      • Medications (hormone based)
      • Medications (Anti- Seizure & Diuretics)
      • Medications (other)
      • Smoking
      • Jack is a 66-year-old male who has been taking prednisone 7.5 mg daily for the past year. Is he at risk to develop osteoporosis?
      • Smoking is a risk factor associated with osteoporosis.
  • Signs and symptoms of osteoporosis
      • Signs & Symptoms
      • Some of the subtle signs of osteoporosis include which of the following?
  • Established screening recommendations for osteoporosis
      • Screening Recommendations - Who Should Be Screened
      • Types of Screening
      • FRAX (WHO Fracture Risk Assessment Tool)
      • Gold Standard of Screening
      • BMD (Bone Mineral Density) Interpretation
      • Gladys is a 65-year-old female who is at her physician's office for her annual physical exam. Her physician wants to screen her for osteoporosis given...
      • Gladys had laboratory tests (serum calcium and Vitamin D) to screen for osteoporosis. These results have come back increased. What laboratory tests sh...
  • Clinical results
      • Biomarkers of Bone Turnover
      • The "Peptides"
      • TRAP & Osteocalcin
      • Clinical Laboratory Tests and Results
      • Which of the following tests is the most sensitive marker of bone formation?
      • Tartrate-resistant acid phosphatase (TRAP) is a version of ________ produced by osteoclasts.
  • References
      • References

Additional Information

Level of Instruction: Intermediate
 
Intended Audience: Medical laboratory scientists, medical laboratory technicians, pathology residents, MLS students, and other health care personnel who have an interest in this subject matter. 
 
Author information: Lynne Brodeur, MA, MLS(ASCP)CM holds a master of arts degree in teaching. She is currently a full time lecturer at the University of Massachusetts Dartmouth and works per diem in Clinical Chemistry at St. Luke's Hospital in New Bedford, MA.
 
Reviewer information: Laura L. Merritt MS, MT(ASCP) is the MLT Program Director at Mercyhurst University and also works in a part time capacity as a Medical Technologist at the VA Medical Center in Erie, Pa. She holds a Bachelor degree in Medical Technology from Gannon University in Erie, completing her clinical certificate at St. Vincent’s school of Medical Technology. She also holds a Master’s degree from Mercyhurst University in Erie.
 
Reviewer Information: Elizabeth Hart, MA, MLS(ASCP)CM is a full-time lecturer at the University of Massachusetts Dartmouth and is also employed in the Transfusion Services Dept. at Brigham and Women's Faulkner Hospital (BWFH) in Boston, MA. She holds a Masters of Arts in Teaching and a Bachelors degree in Clinical Laboratory Science and has been a full-time faculty member in the Dept. of Medical Laboratory Science at UMass Dartmouth since 2003, instructing both lecture and laboratory courses in immunohematology, immunology, and human genetics. At BWFH, she is a senior technologist with 25 years experience in transfusion medicine.

Just one user? Visit LabCE.com for individual subscriptions.
This course is part of:
Osteoclast
Osteoblasts
http://www.boneclinic.com.sg/wp-content/uploads/2011/07/osteoporosis1.jpg